AstraZeneca PLC (AZN.L)
-LSE 3,374.17 
15.33(0.45%) May 17, 11:53AM EDT
| Prev Close: | 3,389.50 |
|---|
| Open: | 3,389.00 |
|---|
| Bid: | 3,382.50 |
|---|
| Ask: | 3,383.50 |
|---|
| 1y Target Est: | 49.34 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3,369.00 - 3,396.00 |
|---|
| 52wk Range: | 2,578.50 - 3,403.50 |
|---|
| Volume: | 2,197,919 |
|---|
| Avg Vol (3m): | 2,380,840 |
|---|
| Market Cap: | 42.18B |
|---|
| P/E (ttm): | 746.33 |
|---|
| EPS (ttm): | 4.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- Impax Labs launches generic version of ZomigAP(Fri, May 17)
- Golden Parachutes Face Clampdown in EU Law on Executive Payat Bloomberg(Thu, May 16)
- AstraZeneca accelerates cancer drug testingat Reuters(Thu, May 16)
- AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trialsat Bloomberg(Thu, May 16)
- Cubist bid for Optimer before sale process began-sourcesat Reuters(Wed, May 15)
- Dish lines up banks to finance Sprint bid: sourcesat Reuters(Wed, May 15)
- Dish lines up banks to finance Sprint bid -sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 billion for Optimer before sale process: sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 bln for Optimer before sale process-sourcesat Reuters(Wed, May 15)
- A Closer Look at AstraZeneca's Dividend Potentialat Motley Fool(Tue, May 14)
- A taste for defensives sours prospects for European stocksat Reuters(Tue, May 14)
- AstraZeneca, Cubist, Astellas Said to Make Bids for Optimerat Bloomberg(Mon, May 13)
- Glaxo, Theravance Win Approval for Lung Disease Treatmentat Bloomberg(Fri, May 10)
- U.S. FDA approves Glaxo/Theravance drug for COPD lung diseaseat Reuters(Fri, May 10)
- Dentsply 1Q income rises, company cuts outlookAP(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 6.71 |
|---|
| P/S (ttm): | 156.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.17 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -1.23 |
|---|
Business Summary
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide.
View More